MD3801536T2 - Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei - Google Patents
Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei Download PDFInfo
- Publication number
- MD3801536T2 MD3801536T2 MDE20210340T MDE20210340T MD3801536T2 MD 3801536 T2 MD3801536 T2 MD 3801536T2 MD E20210340 T MDE20210340 T MD E20210340T MD E20210340 T MDE20210340 T MD E20210340T MD 3801536 T2 MD3801536 T2 MD 3801536T2
- Authority
- MD
- Moldova
- Prior art keywords
- sepiapterin
- pharmaceutically acceptable
- administration
- food
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677943P | 2018-05-30 | 2018-05-30 | |
| US201862771398P | 2018-11-26 | 2018-11-26 | |
| US201962822376P | 2019-03-22 | 2019-03-22 | |
| GC201937663 | 2019-05-28 | ||
| PCT/US2019/034523 WO2019232130A1 (en) | 2018-05-30 | 2019-05-30 | Methods for increasing sepiapterin plasma exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3801536T2 true MD3801536T2 (ro) | 2024-11-30 |
Family
ID=68699037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210340T MD3801536T2 (ro) | 2018-05-30 | 2019-05-30 | Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11617752B2 (enExample) |
| EP (2) | EP3801536B1 (enExample) |
| JP (2) | JP7502197B2 (enExample) |
| CN (1) | CN112703002A (enExample) |
| AU (2) | AU2019277382B2 (enExample) |
| CA (1) | CA3102106A1 (enExample) |
| DK (1) | DK3801536T3 (enExample) |
| ES (1) | ES2986920T3 (enExample) |
| FI (1) | FI3801536T3 (enExample) |
| HR (1) | HRP20241213T1 (enExample) |
| HU (1) | HUE068589T2 (enExample) |
| LT (1) | LT3801536T (enExample) |
| MD (1) | MD3801536T2 (enExample) |
| MX (2) | MX2020012979A (enExample) |
| PL (1) | PL3801536T3 (enExample) |
| PT (1) | PT3801536T (enExample) |
| RS (1) | RS65874B1 (enExample) |
| SI (1) | SI3801536T1 (enExample) |
| SM (1) | SMT202400430T1 (enExample) |
| WO (1) | WO2019232130A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ753504A (en) | 2016-11-29 | 2025-10-31 | Ptc Therapeutics Mp Inc | Polymorphs of sepiapterin and salts thereof |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| CN111491635A (zh) | 2017-09-01 | 2020-08-04 | 显莎制药公司 | 包含墨蝶呤的药物组合物及其用途 |
| JP7547215B2 (ja) | 2018-05-30 | 2024-09-09 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 |
| US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
| WO2021150983A1 (en) * | 2020-01-24 | 2021-07-29 | Ptc Therapeutics Mp, Inc. | Methods for treating parkinson's disease with sepiapterin |
| US20230077104A1 (en) * | 2020-02-19 | 2023-03-09 | The United States Government As Represented By The Department Of Veteran Affairs | L-sepiapterin and methods of use for treating diseases and disorders |
| US20240122931A1 (en) * | 2021-02-09 | 2024-04-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| AU2022221345A1 (en) * | 2021-02-09 | 2023-09-07 | Ptc Therapeutics Mp, Inc. | Methods for treating glioblastomas with sepiapterin |
| CN120732846A (zh) * | 2025-04-09 | 2025-10-03 | 中南大学湘雅医院 | 吲哚乙酸在制备预防或治疗高血压产品中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US5736343A (en) | 1995-08-18 | 1998-04-07 | Landry; Donald | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007511520A (ja) | 2003-11-13 | 2007-05-10 | ザ ジェネラル ホスピタル コーポレーション | 疼痛を治療するための方法 |
| US7732599B2 (en) | 2003-11-17 | 2010-06-08 | Biomarin Pharmaceutical Inc. | Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin |
| CN1894251B (zh) | 2003-11-17 | 2011-06-29 | 默克和西伊公司 | (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型 |
| PL1708690T3 (pl) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| JP2008523090A (ja) | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| BRPI0609421B1 (pt) | 2005-04-28 | 2021-06-01 | Shiratori Pharmaceutical Co., Ltd. | Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| ES2906582T3 (es) * | 2007-04-11 | 2022-04-19 | Biomarin Pharm Inc | Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida |
| US20110144117A1 (en) | 2008-08-12 | 2011-06-16 | Orpha Swiss Gmbh | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin |
| WO2011132435A1 (ja) * | 2010-04-22 | 2011-10-27 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| ES2681345T3 (es) | 2012-05-07 | 2018-09-12 | Shiratori Pharmaceutical Co., Ltd. | Método para producir sepiapterina y tetrahidrolactoilpterina |
| EP3213062B1 (en) * | 2014-10-31 | 2020-02-12 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| NZ753504A (en) | 2016-11-29 | 2025-10-31 | Ptc Therapeutics Mp Inc | Polymorphs of sepiapterin and salts thereof |
| CN111491635A (zh) | 2017-09-01 | 2020-08-04 | 显莎制药公司 | 包含墨蝶呤的药物组合物及其用途 |
| US11335708B2 (en) * | 2017-11-23 | 2022-05-17 | Semiconductor Energy Laboratory Co., Ltd. | Display device having a plurality of thin film transistors per pixel |
| EP3807279B1 (en) | 2018-05-30 | 2025-12-31 | PTC Therapeutics MP, Inc. | Pharmaceutically acceptable sepiapterin salts with improved stability |
| JP7547215B2 (ja) | 2018-05-30 | 2024-09-09 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 |
| US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
| DK4009978T3 (da) | 2019-08-05 | 2024-10-14 | Ptc Therapeutics Mp Inc | Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering |
| ES3041002T3 (en) | 2019-09-25 | 2025-11-06 | Ptc Therapeutics Mp Inc | Methods for treating hyperphenylalaninemia |
-
2019
- 2019-05-30 US US17/059,719 patent/US11617752B2/en active Active
- 2019-05-30 MX MX2020012979A patent/MX2020012979A/es unknown
- 2019-05-30 SM SM20240430T patent/SMT202400430T1/it unknown
- 2019-05-30 MD MDE20210340T patent/MD3801536T2/ro unknown
- 2019-05-30 CA CA3102106A patent/CA3102106A1/en active Pending
- 2019-05-30 EP EP19811888.7A patent/EP3801536B1/en active Active
- 2019-05-30 HU HUE19811888A patent/HUE068589T2/hu unknown
- 2019-05-30 DK DK19811888.7T patent/DK3801536T3/da active
- 2019-05-30 SI SI201930841T patent/SI3801536T1/sl unknown
- 2019-05-30 HR HRP20241213TT patent/HRP20241213T1/hr unknown
- 2019-05-30 AU AU2019277382A patent/AU2019277382B2/en active Active
- 2019-05-30 PL PL19811888.7T patent/PL3801536T3/pl unknown
- 2019-05-30 FI FIEP19811888.7T patent/FI3801536T3/fi active
- 2019-05-30 ES ES19811888T patent/ES2986920T3/es active Active
- 2019-05-30 RS RS20240943A patent/RS65874B1/sr unknown
- 2019-05-30 CN CN201980050839.7A patent/CN112703002A/zh active Pending
- 2019-05-30 EP EP24187175.5A patent/EP4454704A3/en active Pending
- 2019-05-30 JP JP2020566655A patent/JP7502197B2/ja active Active
- 2019-05-30 LT LTEPPCT/US2019/034523T patent/LT3801536T/lt unknown
- 2019-05-30 PT PT198118887T patent/PT3801536T/pt unknown
- 2019-05-30 WO PCT/US2019/034523 patent/WO2019232130A1/en not_active Ceased
-
2020
- 2020-11-30 MX MX2024005935A patent/MX2024005935A/es unknown
-
2023
- 2023-03-31 US US18/129,177 patent/US12329757B2/en active Active
-
2024
- 2024-02-05 JP JP2024015822A patent/JP2024069192A/ja active Pending
-
2025
- 2025-02-06 AU AU2025200814A patent/AU2025200814A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801536B1 (en) | 2024-07-17 |
| SI3801536T1 (sl) | 2024-12-31 |
| MX2024005935A (es) | 2024-06-04 |
| CN112703002A (zh) | 2021-04-23 |
| FI3801536T3 (fi) | 2024-08-29 |
| ES2986920T3 (es) | 2024-11-13 |
| HRP20241213T1 (hr) | 2024-11-22 |
| RS65874B1 (sr) | 2024-09-30 |
| SMT202400430T1 (it) | 2024-11-15 |
| EP4454704A2 (en) | 2024-10-30 |
| WO2019232130A1 (en) | 2019-12-05 |
| JP7502197B2 (ja) | 2024-06-18 |
| US12329757B2 (en) | 2025-06-17 |
| JP2024069192A (ja) | 2024-05-21 |
| US20210220363A1 (en) | 2021-07-22 |
| DK3801536T3 (da) | 2024-08-19 |
| EP3801536A4 (en) | 2022-03-23 |
| AU2019277382B2 (en) | 2025-01-09 |
| MX2020012979A (es) | 2021-04-29 |
| HUE068589T2 (hu) | 2025-01-28 |
| CA3102106A1 (en) | 2019-12-05 |
| AU2019277382A1 (en) | 2021-01-21 |
| PL3801536T3 (pl) | 2025-02-03 |
| LT3801536T (lt) | 2024-09-25 |
| AU2025200814A1 (en) | 2025-02-27 |
| JP2021525729A (ja) | 2021-09-27 |
| US20230381181A1 (en) | 2023-11-30 |
| EP3801536A1 (en) | 2021-04-14 |
| PT3801536T (pt) | 2024-09-19 |
| US11617752B2 (en) | 2023-04-04 |
| EP4454704A3 (en) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3801536B1 (en) | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure | |
| US12213982B2 (en) | Pharmaceutical compositions comprising sepiapterin and uses thereof | |
| US20250195529A1 (en) | Compositions and methods for increasing tetrahydrobiopterin plasma exposure | |
| HK40051961B (en) | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure | |
| HK40051961A (en) | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure | |
| HK40119071A (en) | Methods for increasing sepiapterin plasma exposure | |
| US20240115572A1 (en) | Methods for treating glioblastomas with sepiapterin | |
| US20240122931A1 (en) | Methods for treating covid-19 with sepiapterin | |
| BR112020024346A2 (pt) | métodos para aumentar a exposição de sepiapterina no plasma |